You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CARNITOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Carnitor, and when can generic versions of Carnitor launch?

Carnitor is a drug marketed by Leadiant Biosci Inc and is included in three NDAs.

The generic ingredient in CARNITOR is levocarnitine. There are four drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the levocarnitine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Carnitor

A generic version of CARNITOR was approved as levocarnitine by HIKMA on March 29th, 2001.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CARNITOR?
  • What are the global sales for CARNITOR?
  • What is Average Wholesale Price for CARNITOR?
Summary for CARNITOR
Drug patent expirations by year for CARNITOR
Drug Prices for CARNITOR

See drug prices for CARNITOR

Recent Clinical Trials for CARNITOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Children's Oncology GroupPhase 3
M.D. Anderson Cancer CenterPhase 2
National Cancer Institute (NCI)Phase 2

See all CARNITOR clinical trials

Pharmacology for CARNITOR
Drug ClassCarnitine Analog

US Patents and Regulatory Information for CARNITOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 AP RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Leadiant Biosci Inc CARNITOR levocarnitine TABLET;ORAL 018948-001 Dec 27, 1985 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Leadiant Biosci Inc CARNITOR levocarnitine SOLUTION;ORAL 018948-002 Apr 27, 1988 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Leadiant Biosci Inc CARNITOR levocarnitine SOLUTION;ORAL 019257-001 Apr 10, 1986 AA RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Leadiant Biosci Inc CARNITOR SF levocarnitine SOLUTION;ORAL 019257-002 Mar 28, 2007 AA RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CARNITOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 ⤷  Subscribe ⤷  Subscribe
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 ⤷  Subscribe ⤷  Subscribe
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CARNITOR

See the table below for patents covering CARNITOR around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1257266 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 0152836 ⤷  Subscribe
Australia 3050201 ⤷  Subscribe
Canada 2381187 CARNITINE PAR INTRAVEINEUSE DESTINEE AU TRAITEMENT DE PATIENTS SOUFFRANT D'UREMIE CHRONIQUE SOUMIS A UNE DIALYSE PERIODIQUE (INTRAVENOUS CARNITINE FOR THE TREATMENT OF CHRONIC URAEMIC PATIENTS UNDERGOING PERIODICAL DIALYSIS) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

CARNITOR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for L-Carnitine (CARNITOR)

Introduction

L-Carnitine, often marketed under the brand name CARNITOR, is a naturally occurring amino acid derivative that plays a crucial role in energy production and has various health benefits. Here, we delve into the market dynamics and financial trajectory of L-Carnitine, highlighting its growth prospects, key drivers, and regional performance.

Global Market Size and Growth

The global L-Carnitine market was valued at USD 203.4 million in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 4.9% from 2023 to 2030, reaching approximately USD 298.7 million by 2030[1].

Key Drivers of Market Growth

Several factors are driving the growth of the L-Carnitine market:

Health-Conscious Consumer Base

The increasing awareness and demand for health and wellness products are significant drivers. Consumers are more inclined towards functional foods and beverages that include L-Carnitine due to its benefits in muscle repair, reduction in muscle soreness, and overall health improvement[1].

Animal Feed Industry

The demand for L-Carnitine in animal feed is rising, particularly in the poultry and swine sectors. L-Carnitine supplementation enhances the development, performance, and reproductive health of animals, which is crucial for the meat industry[2].

Post-Exercise Recovery and Weight Management

The use of L-Carnitine for post-exercise recovery, weight management, and healthy aging is gaining traction. This has led to an increased demand for L-Carnitine supplements, especially among fitness enthusiasts and athletes[1].

Regional Analysis

North America

North America dominates the L-Carnitine market, with a revenue share of 37.9% in 2022. The region is expected to grow at a CAGR of 5.3% during the forecast period, driven by the expansion of the health-conscious consumer base and significant market participants in the pharmaceutical sector[2].

Europe

Europe is another significant market, expected to grow at a CAGR of 4.9% during the forecast period. The nutraceutical industry in Europe is expanding due to increased purchases of supplements as a preventative measure for health problems. The preference for herbal remedies over pharmaceuticals also contributes to the growth[2].

Asia-Pacific

The Asia-Pacific region is witnessing growth due to a large population and an increasing industrial sector. The demand for functional food products and beverages, as well as protein-rich food products for dairy and pet animals, is driving the market in this region[4].

Market Segmentation

By Process

The global L-Carnitine market is bifurcated into chemical synthesis and bioprocess. The bioprocess segment is the highest contributor and is expected to grow at a CAGR of 5.3% during the forecast period[2].

By Product

The market is segmented into food and pharma grade and feed grade. The food and pharma grade segment holds the highest market share and is expected to grow at a CAGR of 5.4% during the forecast period[2].

By Application

The market is segmented into animal feed, healthcare products, functional food and beverages, and medicines. The healthcare products segment is the highest contributor and is expected to grow at a CAGR of 5.3% during the forecast period[2].

Competitive Landscape

The global L-Carnitine market is highly competitive, with key players such as Lonza, Northeast Pharmaceutical Group Co., Ltd. (NEPG), Biosint S.p.A., Cayman Chemical, Merck KGaA, and others. These companies are investing significantly in research and development to enhance their products and maintain market share[2].

Research and Development

Rising investments in research and development are creating tremendous opportunities for the L-Carnitine market. Companies are focusing on improving the quality and efficacy of L-Carnitine products, which is expected to drive market growth[2].

Market News and Developments

Recent developments, such as Lonza's announcement to build a commercial medicinal product fill and finish facility, indicate the industry's commitment to expanding its capabilities and meeting growing demand[2].

Financial Trajectory

The financial trajectory of the L-Carnitine market is positive, with steady growth projected over the next several years. Here are some key financial highlights:

  • Market Size: Expected to reach USD 298.7 million by 2030 from USD 203.4 million in 2022[1].
  • CAGR: 4.9% from 2023 to 2030[1].
  • Regional Growth: North America and Europe are expected to be significant contributors, with CAGRs of 5.3% and 4.9%, respectively[2].

Key Takeaways

  • The global L-Carnitine market is driven by a health-conscious consumer base, increasing demand from the animal feed industry, and rising use in post-exercise recovery and weight management.
  • North America and Europe are the dominant regions, with significant growth expected in the Asia-Pacific region.
  • The bioprocess segment and food and pharma grade products are leading the market.
  • Healthcare applications are the largest segment, driven by the benefits of L-Carnitine in muscle repair and overall health.

FAQs

What is the current market size of the global L-Carnitine market?

The global L-Carnitine market was valued at USD 203.4 million in 2022[1].

What is the expected CAGR of the global L-Carnitine market from 2023 to 2030?

The global L-Carnitine market is expected to grow at a CAGR of 4.9% from 2023 to 2030[1].

Which region dominates the L-Carnitine market?

North America dominates the L-Carnitine market, with a revenue share of 37.9% in 2022[2].

What are the primary applications of L-Carnitine?

The primary applications include animal feed, healthcare products, functional food and beverages, and medicines. Healthcare products are the largest segment[2].

Who are the key players in the global L-Carnitine market?

Key players include Lonza, Northeast Pharmaceutical Group Co., Ltd. (NEPG), Biosint S.p.A., Cayman Chemical, Merck KGaA, and others[2].

Sources

  1. Grand View Research: L-carnitine Market Size, Share & Trends Analysis Report, 2030.
  2. GlobeNewswire: Global L-Carnitine Market Size is Estimated to Reach USD 267.60 million by 2030.
  3. Maximize Market Research: L-Carnitine Market Global Industry Analysis and Forecast (2024-30).

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.